Author + information
For the purpose of determining the risk factors for coronary artery disease, the living style and medication usage, and complying with the newest guidelines, and to evaluate the changes seen by the passing time Turkey and Europe have been compared in view of the results of EUROASPIRE III and a study from one of the Asian countries, namely Kyrgyzstan.
Longitudinal observational study of two population-based cohorts. Setting 1067 patients with coronary artery disease diagnosis were retrospectively studied. During studying these patients, they were interviewed and examined at least a year after the initial coronary event and/or intervention. Participants The EUROASPIRE III survey was carried out in 2006-2007 in 76 centres from selected geographical areas in 22 countries in Europe and 20 centers in Kyrgyzstan. Measurements Although there was not a big difference for the classical risk factors between Turkey's results and EUROASPIRE III results, in Kyrgyzstan.
The gender distribution of the 1067 patients in the study was recorded as 658 female (61.7%) and 409 male (38.3%), and the average age was 68.3±13.7. The number of patients seen after the coronary event in Kyrgyzstan was 524 (49.1%). Results smoking (75%), hypertension (84%), dyslipidemia (86.5%), diabetes (74.4%) were much higher compared to the other countries. The biggest difference between Kyrgyzstan and the other countries in EUROASPIRE III Study including Turkey was the rarity of medical treatment (78%) and interventional treatment (1.9%). Also, post coronary event smoking cessation (27.4% vs 70.8% (Europe)), physical activity (17.5 % vs 59.1% (Europe)), weight loss (37.2% vs 58.2% (Europe)) ratios were found to be much less between Kyrgyz and EUROASPIRE III studies. In Kyrgyzstan and Turkey the ratios of young patients were found to be higher comparing to the other European countries (<50y: 28.3% (K), 20% (T), and 12.7% (E) of all of the patients, respectively).
When compared to the results of EUROASPIRE III study of Turkey and Europe the Kyrgyzstan results found to be behind for prevention, follow up and treatment goals set by the guidelines.